Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ADC Therapeutics SA ADCT

Healthcare Biotechnology
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The... see more

Recent & Breaking News (NYSE:ADCT)

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

GlobeNewswire April 4, 2024

ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024

GlobeNewswire April 3, 2024

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

GlobeNewswire April 1, 2024

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

GlobeNewswire March 13, 2024

ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit

GlobeNewswire March 6, 2024

ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024

GlobeNewswire March 6, 2024

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire March 5, 2024

ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

GlobeNewswire February 27, 2024

ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards

GlobeNewswire January 4, 2024

ADC Therapeutics Provides Business Updates

GlobeNewswire January 4, 2024

ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

GlobeNewswire December 12, 2023

ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards

GlobeNewswire November 7, 2023

ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

GlobeNewswire November 7, 2023

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

GlobeNewswire November 6, 2023

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting

GlobeNewswire November 2, 2023

ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023

GlobeNewswire October 24, 2023

ADC Therapeutics to Participate in September Investor Conferences

GlobeNewswire September 5, 2023

ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)

GlobeNewswire August 30, 2023

ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

GlobeNewswire August 8, 2023

ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

GlobeNewswire August 1, 2023